Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00862108

Enrollment

Registered

2009-03-16

Start date

2008-09-30

Completion date

2010-03-31

Last updated

2009-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

Attention Deficit Hyperactivity Disorder, Polymorphism, Single Nucleotide, SLC6A2 protein, human, ADRA2A protein, human

Brief summary

The purpose of this study is to determine whether norepinephrine gene polymorphism affect to treatment response in ADHD

Interventions

DRUGMethylphenidate

mg/kg dose: 0.7\ 1.2mg/kg PO daily morning intake 8 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Years to 18 Years

Healthy volunteers

Inclusion criteria

* diagnosis made by DSM-IV and K-SADS-PL * IQ \> 71

Exclusion criteria

* genetic disorder * history of acquired brain injury * seizure disorder * other neurologic disorder * mental disorder, pervasive developmental disorder * obsessive-Compulsive disorder * communication disorder * learning disorder

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression Scale-Improvement	8 weeks

Secondary

Measure	Time frame
ADHD rating scale	8 weeks

Countries

South Korea

Contacts

Primary ContactSoo-Churl Cho, MD, PhD

jewook.kang@gmail.com82-2-2072-3648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026